阮健 - 浙江大学

个人简介

浙江大学附属第一医院-肿瘤内科（一）副主任（主持工作）主任医师研究员博士生导师，主要从事原发性肝癌的临床及基础研究工作。以第一或者共同通讯作者在Advanced materials、Nature communications、Cancer immunology research、Brief Bioinform及Molecular cancer等杂志发表了多篇论文。主持国家级课题3项及省级课题3项。参编著作3本，包括《肿瘤生物及分子靶向治疗的应用及护理》（副主编）、《肿瘤生物治疗学》及《肿瘤生物治疗新进展》（编者）。学术任职：中国抗癌协会第一届青年理事会理事；中国抗癌协会国际交流专委会常委；中国抗癌协会肿瘤靶向治疗专委会委员；浙江省医师协会肿瘤精准治疗专委会青委副主委；广东省杰出青年医学人才；浙江大学临床百人计划引进人才

研究领域

肝脏肿瘤及胸部肿瘤的发病机制研究

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Bao X(#), Li Q(#), Chen J(#), Chen D(#), Ye C(#), Dai X, Wang Y, Li X, Rong X, Cheng F, Jiang M, Zhu Z, Ding Y, Sun R, Liu C, Huang L, Jin Y, Li B, Lu J, Wu W, Guo Y, Fu W, Langley SR, Tano V, Fang W, Guo T, Sheng J(*), Zhao P(*), Ruan J(*).Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multi-Omics Analysis.Cancer Immunol Res. 2022Ma; 20; canimm. 1101. 2022-1-309:35:19.220.doi:10.1158/2326-6066.CIR-21-1101.（Q1，影响因子：12.020，封面文章） Ruyin Chen(#), Dandan Zheng(#), Qiong Li(#), Shuaishuai Xu, Chanqi Ye, Qi Jiang, Feifei Yan, Yunlu Jia(*), Xiaochen Zhang(*), Jian Ruan(*)，Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.Cancer Lett. 2022 Jul 31;215853.（Q1，影响因子：9.756） Xiaomeng Dai(#) , Jian Ruan(#) , Yixuan Guo(#) , Zhu Sun , Junqing Liu, Xuanwen Bao , Hangyu Zhang , Qiong Li , Chanqi Ye , Xun Wang , Chun-Xia Zhao , Feng Zhou, Jianpeng Sheng(*), Dong Chen(*), Peng Zhao(*),Enhanced radiotherapy efficacy and induced anti-tumor immunity in HCC by improving hypoxia microenvironment using oxygen microcapsules. Chemical Engineering Journal 2021 422 (2021) 130109.（Q1，影响因子：16.744） Li Q, Ye C, Tian T, Jiang Q, Zhao P, Wang X, Liu F, Shan J, Ruan J(*).The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeutics.Cell Death Dis.2022 May 4;13(5):434.（Q1影响因子：9.685） Dong Chen(#), Xuanwen Bao(#), Ruyi Zhang(#), Yongfeng Ding, Min Zhang, Benfeng Li, Hangyu Zhang, Xiaolin Li , Zhou Tong, Lulu Liu, Xiaohu Zhou, Saisai Wang, Xiaofei Cheng, Yi Zheng , Jian Ruan(*), Weijia Fang(*), Peng Zhao(*)；Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.British journal of cancer 2021.（Q1影响因子：9.812） Chen R(#), Li Q(#), Xu S(#), Ye C, Tian T, Jiang Q, Shan J, Ruan J(*) . Modulationof the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.CANCER CELL INT.2022 Feb 11;22(1):73.（影响因子：6.429） Li Q, Cao M, Yuan G, Cheng X, Zang M, Chen M, Hu X, Huang J, Li R, Guo Y, Ruan J(*), Chen J(*).Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.Front Oncol.2022 Feb 24;12:809709（Q2，影响因子：6.244） Shuaishuai Xu , Chanqi Ye , Ruyin Chen , Qiong Li, Jian Ruan(*)The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.Cancers 2022（Q2，影响因子：6.575） Qi Jiang, Mixue Xie, Ruyin Chen, Feifei Yan, Chanqi Ye, Qiong Li, Shuaishuai Xu, Wei Wu, Yunlu Jia, Peng Shen, Jian Ruan(*) Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.Front Immunol. 2022 Aug 29;13:973601.（Q2，影响因子：8.786） Zhen Zhai （#）, Jian Ruan （#）, Yi Zheng, Dong Xiang , Na Li ，Yujiao Deng 1 2, Jia Yao, Peng Zhao , Shuqian Wang , Si Yang, Linghui Zhou , Ying Wu , Peng Xu, Lijuan Lyu , Jun Lyu , Raymond Bergan , Tianhui Chen , Zhijun Dai（*）.Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017.JAMA Netw Open. 2021 Aug 2;4(8):e2120360.（Q1，影响因子：13.353） Feiye Liu(#), Yanjun Cai(#), Xiaoxiang Rong(#), Jinzhang Chen,Dayong Zheng, Lu Chen, Junyi Zhang, Rongcheng Luo, Peng Zhao, Jian Ruan(*), MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer. MOL CANCER 2017,16:122.（Q1，影响因子：41.444） Jian Ruan(#)(*)，Haiyan Zheng(#)，Xiaodong Rong，Xiaomin Rong，Junyi Zhang，Weijia Fang，Peng Zhao，Rongcheng Luo, Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. MOL CANCER 2016,15:17. （Q1，影响因子：41.444）